Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

Cardio Block > Pharmacology Of Antihypertensives > Flashcards

Pharmacology Of Antihypertensives Flashcards

1
Q

AHA and WHO definitions of hypertension

A

AHA: 140/90
WHO: 160/95

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Hypertension diagnostic criteria

A

Two or more readings greater than normal at least 2-4 weeks apart

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Two types of hypertension and their prevalence

A 
Essential/primary = 90%: idiopathic, genetic basis for incidence most often found in middle-aged adults
Non-essential/secondary = 10%: clinically identifiable cause
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Therapy choices for HTN depend on what kind of factors? (9)

A
  1. Age
  2. Ethnicity (37-40% African American men and women are currently being treated for HTN and 25% of US citizens overall are being treated for HTN)
  3. Body-type
  4. Obesity
  5. Personality type
  6. Athletic or sedentary lifestyle
  7. Etiology of HTN
  8. Rapidity of onset and severity
  9. Presence of other risk factors for CV disease
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Lifestyle modifications for HTN management (8)

A
  1. Weight loss
  2. Limit alcohol intake (less than 1 oz per day)
  3. Aerobic physical activity (30-45 min per day)
  4. Reduce Na+ intake to less than 100mmol (6g) per day
  5. Maintain intake of K+ to 90mmol (7g) per day
  6. Maintain intake of Ca2+ and Mg2+
  7. Smoking cessation
  8. Reduce dietary sugar, saturated fat, and cholesterol intake
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

HTN considerations for patients (5)

A
  1. Once initiated, treatment is usually for life
  2. Financial cost
  3. Dosage should be carefully considered due to side effects and drug interactions
  4. Patient compliance
  5. Consider the Step-Care Therapy approach
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Step Care Therapy (4)

A
  1. Lifestyle Modifications
    • ACEI/ARB
    • higher drug dose/substitute for another drug/add second drug
    • second or third agent (at least one should be a diuretic)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

For each agent considered for HTN management, you must also consider what?

A

The baroreceptor reflex!

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

The baroreceptor reflex does what?

A

Attemps to lower pressure activates reflex mechanisms that then act to raise the pressure: Na+ and H2O retention by the kidneys, sympathetically-induced increases in peripheral vascular resistance, heart rate, and cardiac output.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Diuretics (General, MOA, Efficacy)

A

General: Includes thiazides, loop diuretics, K+-sparing diuretics.

MOA: Relatively unknown. Appears to decrease blood volume resulting in a decrease in CO.
Indapamide also has direct vasodilating properties.

Efficacy: Moderate monotherapy, 20/10, but augments antihypertensive effects of other drugs. Greater efficacy in African-Americans and elderly patients.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Diuretics (Pharmacokinetics, ADRs, Contraindications)

A

PK: Taken PO with onset of action in 2-4 weeks; peak effects in 3-4 months. No additional efficacy from increased dosage, but incidence and severity of ADRs increase.

ADRs:

  1. Hyperuricemia
  2. Hypokalemia

Contraindications:

  1. Diabetes (may induce hyperglycemia)
  2. Hyperlipidemia (tend to elevate LDL and triglycerides)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Beta-adrenergic antagonists [Beta Blockers] (General, MOA, Efficacy)

A

General: Propranolol (competitive, non-selective beta receptor antagonist)

MOA: Blocks beta-1 and beta-2 receptors. Decreases HR and contractility to decrease BP. Also decreases renin release and angiotensin II formation.

Efficacy: Moderate in monotherapy, better in combination therapy. Smokers respond poorly to these agents.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Beta-adrenergic antagonists [Beta Blockers] (Pharmacokinetics, ADRs, and Considerations)

A

PK: PO/IV, lipophilic (wide distribution), extensive first-pass metabolism with production of active metabolites

ADRs: 7-9% of patients discontinue use

  1. Minor GI and CNS nausea
  2. Asthma exacerbation
  3. Hyperlipidemia (increases triglycerides and lowers HDL)
  4. Male sexual dysfunction
  5. Diabetes (masks signs and symptoms of hypoglycemia which may lead to increased incidence of coma and death)
  6. CHF exacerbation

Considerations (labetalol and carvedilol):

  1. Block beta-1, beta-2, alpha-1
  2. Very good efficacy in lowering BP especially in presence of HF
  3. PO for long-term management of CHF and HTN; IV for HTN emergencies
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Centrally-acting Sympatholytics [Clonidine] (General, MOA, Efficacy)

A

General: Clonidine has a number of clinical uses

MOA: Post-synaptic alpha-2 agonist in CNS - inhibits sympathetic outflow at the level of the NTS resulting in decreased HR and TPR. Acts upon presynaptic alpha-2 agonists in the periphery - decreased NE release from postganglionic nerve terminals.

Efficacy: 35/20, monotherapy (combination with a diuretic is common).

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Centrally-acting Sympatholytics [Alpha-Methyldopa] (General, MOA, ADRs)

A

General: Analog of DOPA, converted in CNS neurons to alpha-methylnorepinephrine

MOA: Stimulates inhibitory presynaptic alpha-2 receptors. Acts as “false transmitter” at post-synaptic terminals. Drug choice for treatment of chronic HTN in women during child-bearing years.

ADRs:

  1. Prominent sexual dysfunction
  2. Dry mouth
  3. Sedation
  4. Positive direct Coombs test producing frank hemolytic anemia
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Peripherally-acting Sympatholytics [Reserpine] (General, MOA, Efficacy)

A

General: Diminished use due to CNS effects

MOA: Destroys both central and peripheral catecholamine storage granules in nerve terminals (NE, 5-HT, and DA) - produces a tremendous decrease in SNA and increases parasympathetic tone; prominent decrease in HR, MAP, CO, and renal function

Efficacy: 5/5, monotherapy, 15/10 with diuretic

17
Q

Peripherally-acting Sympatholytics [Reserpine] (Pharmacokinetics and ADRs)

A

PK: Rapid oral absorption; onset of action observed within 2-3 weeks. Highly lipid soluble (access to CNS). Half life = 33 hours (full recovery can take weeks)

ADRs:

  1. Parkinson-like syndrome (extrapyramidal effect)
  2. GI disorders (increases parasympathetic tone)
  3. Male sexual dysfunction
  4. Prominent orthostatic hypotension
18
Q

Peripherally-acting Sympatholytics [Trimethaphan - Discontinued] (General, MOA, Efficacy)

A

General: Autonomic ganglion-blocking action.

MOA: Nicotinic receptor antagonists. Produces a significant decrease in peripheral sympathetic and parasympathetic activity. Use in controlled management in MAP during aortic dissection and other surgery.

19
Q

Peripherally-acting Sympatholytics [Trimethaphan - Discontinued] (Pharmacokinetics, ADRs)

A

PK: Short half-life with reversal of effects in 10-30 minutes after discontinuation.

ADRs:
1. Prominent orthostatic hypotension

20
Q

Peripherally-acting Sympatholytics [Prazosin, Terazosin, Doxazosin, etc.] (General, MOA, Efficacy, and ADRs)

A

General: Added benefits include lowered LDL and total cholesterol.

MOA: Selective antagonist at vascular smooth muscle alpha-1 receptors; by sparing alpha-2 presynaptic receptors, NE release is not induced

Efficacy: 15/10, monotherapy; 25/15 with diuretic.

ADRs:

  1. Mild tolerance development to antihypertensive effect
  2. Reflex tachycardia
  3. Sexual dysfunction
21
Q

Calcium Channel Antagonists [Verapamil, Diltiazem] (MOA, Pharmacokinetics, Efficacy, and ADRs)

A

MOA: Direct vasodilator activity by inhibiting both Ca2+ entry into vascular smooth muscle and Ca2+ release from the SR.

PK: IV/PO (extended-release PO prep available)

Efficacy: Verapamil, 30/20, diltiazem, 20/15

ADRs:

  1. Cardiodepression (may counteract reflex tachycardia)
  2. Others as an antidysrhythmic agent
22
Q

Calcium channel antagonists [Nifedipine] (General, MOA, Efficacy, and ADRs)

A

General: Dihydropyridine class of CCB

MOA: Direct vasodilator activity by inhibiting both Ca2+ entry into vascular smooth muscle and Ca2+ release from the SR. Greater vascular effect than verapamil/diltiazem. Significantly less cardiodepressant activity.

Efficacy: 30/20

ADRs:
1. Prominent reflex tachycardia (use with beta blockers!)

23
Q

Direct-acting vasodilators [Hydralazine] (MOA, Efficacy, and Considerations)

A

MOA: Direct vasodilation via guanylate cyclase stimulation (similar to nitrovasodilators). Increases intracellular cGMP activation. Increases Ca2+ sequestration = smooth muscle relaxation. Primary effect on arterioles (afterload) with little effect on venous tone (preload).

Efficacy: 25/25

Considerations: Tolerance development (tachyphylaxis) - due to prominent baroreflex perturbation leading to increased HR, CO, and Na+/H2O retention (sympathetic stimulation of renin release). Beta blockers and diuretics as concomitant therapy.

24
Q

Direct-acting vasodilators [Hydralazine] (ADRs)

A
  1. SLE-like symptoms (metabolism by N-acetylation)
  2. Palpitations, tachycardia
  3. Use limited to resistant, fulminant hypertension and management of hypertensive emergency
25
Q

Direct-acting vasodilators [Minoxidil] (General, MOA, and Considerations)

A

General: Topical (Rogaine) for alopecia. Oral (Loniten) for HTN. Loniten used only for severe, refractory HTN.

MOA: Direct arteriolar vasodilation via stimulation of vascular smooth muscle K+ channel opening resulting in membrane hyperpolarization.

Considerations: Tachyphylaxis due to baroreflex-mediated increases in sympathetic tone. Use in combination with beta blockers and diuretics.

26
Q

Direct-acting vasodilators [Sodium Nitroprusside] (General, MOA, and ADRs)

A

General: Parenterally infused agent use in HTN emergencies and rapid management of CHF. Very potent vasodilator with rapid onset and short duration of action. Decreases both afterload and preload (venodilation).

MOA: Like other nitrovasodilators. Donates NO (EDRF) to increase cGMP-mediated Ca2+ sequestration.

ADRs:
1. Extended continuous infusion may produce methemoglobinemia, cyanide poisoning, and cell death due to inhibition of cellular respiration.

27
Q

Angiotensin converting enzyme inhibitors (ACE-I) [Captopril, enalapril, lisinopril, etc.] (MOA)

A

MOA: Blocks conversion of angiotensin I to angiotensin II, reducing vasoconstriction at the level of the arterioles and inhibiting aldosterone secretion from the adrenal glands.

28
Q

Angiotensin converting enzyme inhibitors (ACE-I) [Captopril, enalapril, lisinopril, etc.] (Pharmacokinetics, Efficacy, and ADRs)

A

PK: PO administration. Should be taken without food. Maximal effects in 4-8 weeks.

Efficacy: 25/20. Less efficacy in African-Americans as monotherapy.

ADRs:

  1. Dry, persistent cough
  2. Proteinuria, angioedema
  3. Maculopapillary rash and altered taste sensation
  4. Pregnancy contraindication!
29
Q

Angiotensin receptor blockers (ARBs) [Losartan, candesartan, irbesartan, valsartan, etc.] (General, MOA, and ADRs)

A

General: newest anti-HTN drug class. Most popular anti-HTN drug class due to minimal ADRs.

MOA: Specific antagonists of angiotensin II at AT1 receptors on vascular smooth muscle. Losartan is a competitive antagonist (half life = 2 hours).

ADRs:

  1. Relatively few
  2. Pregnancy contraindication!

Cardio Block (9 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions